MarketPulse

biologic therapy

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Argenx's Vyvgart Poised for Explosive Growth as Autoimmune Market Expands

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.
ARGXFUJIYVYVGARTbiologic therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Skeletal Dysplasia Market Set to Surge 54% to $5.37B by 2032

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.
PFENVSRAREREGNBMRNrare diseasebiologic therapy
BenzingaBenzinga··Vandana Singh

Argenx Reports Phase 3 Success for VYVGART in Ocular Myasthenia Gravis

Argenx's VYVGART achieves Phase 3 success for ocular myasthenia gravis, meeting primary endpoint. Company plans FDA application to expand indication for the rare eye disorder treatment.
ARGXPhase 3 clinical trialFDA approval